Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Feb 1;2(2):e22730.

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy.

Author information

  • 1Department of Melanoma Medical Oncology; MD Anderson Cancer Center; Houston, TX, USA ; Immunology Program; Graduate School of Biomedical Science; University of Texas Health Science Center at Houston; Houston, TX USA.


In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy.


C-KIT mutant tumors; anti-OX40; dasatinib; immunotherapy; targeted therapy

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk